NASDAQ:SABS | Free Cash Flow | SAB Biotherapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$14.27M$983,257.00-$15.25M
2025-12-31-$16.78M
2025-03-31-$7.8M
2024-12-31-$9.53M$55,377.00-$9.59M
2024-03-31-$10.75M$129,074.00-$10.88M
2023-12-31-$13.45M$67,864.00-$13.51M
2023-03-31-$1.61M$21,300.00-$1.63M
2022-12-31-$1.56M$117,754.00-$1.67M
2022-03-31-$9.54M$1.36M-$10.9M-1105.13%
2021-12-31-$4.88M$2.36M-$7.24M
2021-03-31$9.45M$1.89M$7.56M536.47%

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$44.78M$933,156.00-$45.71M-344.35%
2024-12-31-$34.29M$337,262.00-$34.63M
2023-12-31-$25.12M$197,154.00-$25.32M
2022-12-31-$23.46M$2.17M-$25.63M
2021-12-31$1.99M$10.94M-$8.96M
2020-12-31$10M$12.73M-$2.73M-13.55%

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.